Table 3.
Clinical outcomes after diagnosis of membranous nephropathy
| No. | Treatment | FU (months) | Renal outcome | Last CD4 | Last HIV* | Last sCr | Last UPCR (g/g)** | Serum anti-PLA2R*** |
|---|---|---|---|---|---|---|---|---|
| 1 | ACEi/ARB; MMF; Pred; ARV then MMF switched to CYC within 1 yr | 145 | ESRD/Dialysis | 806 | Undet. | 4.4 | 8.4 | NP |
| 2 | ACEi/ARB; MMF; Pred; ARV | 140 | ESRD/Dialysis; Transplant | 599 | Undet. | 7.2 | 7.2 | NP |
| 3 | – | 81 | Non-ESRD | 161 | Undet. | 0.95 | Undet. | NP |
| 4 | Discontinuation of Tenofovir | 54 | Non-ESRD | 216 | 2190 | 1.27 | – | NP |
| 5 | ACEi/ARB; PredTac; then Ritux; mPred | 9 | Non-ESRD | 971 | Undet. | 1.16 | 11.9 | 153 RU/mL |
| 6 | ACEi/ARB; Pred; then CYC added | 9 | Non-ESRD | 244 | Undet. | 2.73 | 2.02 | < 1:10 |
| 7 | ACEi/ARB | 4 | Non-ESRD | 243 | Undet. | 1.9 | 1.0 | < 1:10 |
| 8 | – | 114 | Non-ESRD | – | – | 0.89 | – | NP |
| 9 | ACEi/ARB;Pred;CYC | 20 | ESRD/dialysis | – | Undet. | – | – | NP |
| 10 | ACEi/ARB | 42 | Non-ESRD | – | Undet. | “normal” | Undet. | NP |
| 11 | ACEi/ARB | 44 | Non-ESRD | 1117 | Undet. | 2.8 | 0.25 | NP |
Abbreviations: FU: Follow-up; sCr: serum creatinine; UPCR: urine protein-to-creatinine ratio; MMF: mycophenolate mofetil; Pred: prednisone; ARV: antiretroviral therapy; ACEi/ARB: Angiotensin converting enzyme inhibitor/angiotensin receptor blocker; Tac: Tacrolimus; Ritux: Rituximab; mPred: methylprednisolone; CYC: cyclophosphamide; Undet.: undetectable; NP: Not performed.*Undet. refers to undetectable HIV-1 RNA levels, the lower limit of detection being < 75 copies/mL.**Undet. refers to undetectable urine protein by dipstick analysis. *** < 1:10 refers to a negative titer of serum anti-PLA2R antibodies